Clinical trials: Alzheimers Disease
Alzheimer Disease
Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered
The purpose of this study is to evaluate the effects of multiple doses of verapamil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and tolerability of…
- Trial name
- NCT00745576
- Testing
- SAM-531
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mild and Moderate Alzheimer's Disease, Cognitively Healthy People
An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population
Difference in nutritional status between patients with mild and moderate Alzheimer's Disease (AD) and cognitively intact healthy people in an Asian population
- Trial name
- NCT02249468
- Where
- Singapore
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Danone Nutricia Research
Dementia, Alzheimer's Disease
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
- Trial name
- NCT00104273
- Testing
- Rasagiline
- Where
- 58 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Maximum Diagnostic Mass of [18Fluor]AZD4694
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress…
- Trial name
- NCT01325402
- Testing
- [18Fluor]AZD4694
- Where
- 2 sites in Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.
Alzheimer Disease
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's…
- Trial name
- NCT00414622
- Testing
- DMXB-A
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- CoMentis
Alzheimer´s Disease
Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
The study is carried out in order to investigate if [11C]AZD2995, compared to [11C]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain.
- Trial name
- PET (NCT00692705)
- Testing
- Radioligand (11C)AZD2995, Radioligand (11C)AZD2184
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer Disease
Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD)
This is a prospective open comprehensive proof-of-principle pilot study.
- Trial name
- NCT04333329
- Testing
- NEUROLITH
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Storz Medical AG
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer´s Disease
Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
The purpose of this study is to evaluate if 4 escalating doses during 20 weeks of NP031112 are safe and tolerated in patients with Alzheimer´s disease.
- Trial name
- NCT00948259
- Testing
- NP031112
- Where
- 3 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Noscira SA
Alzheimer Disease, Dementia
Assistive Technology and Reduced Caregiver Burden
The study investigated a six-week randomized controlled trial study in a small cohort of 16 family caregivers of individuals living with Alzheimer's disease and related dementias.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life
- Trial name
- ck (NCT05352529)
- Testing
- The MapHabit system, Dementia educational videos
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- MapHabit, Inc.
Alzheimer Disease
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.
- Trial name
- NCT04735536
- Testing
- CT1812
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Cognition Therapeutics
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more…
- Trial name
- NCT05908695
- Testing
- GV-971
- Where
- 50 sites in China
- Volunteers
- 1,312 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA…
- Trial name
- NCT06322667
- Testing
- No Intervention
- Where
- 3 sites in Japan
- Volunteers
- 5,000 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Disease
Multiple Dose Japanese Bridging Study
The purpose of this study is to assess the safety and tolerability of multiple oral daily doses of BMS-708163 in healthy young male subjects
- Trial name
- NCT01057030
- Testing
- BMS-708163
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed…
- Trial name
- NCT02600130
- Testing
- Longeveron Mesenchymal Stem Cells
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Longeveron Inc.
Alzheimer's Disease (AD)
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and…
- Trial name
- NCT02681172
- Testing
- Neuraceq (florbetaben 18F), PET
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.
The present pharmacokinetic study is designed to compare bioavailability and assess bioequivalence of two Rosiglitazone XR formulations produced at two different sites.Both formulations will be tested in fasting healthy volunteers
- Trial name
- NCT00468897
- Testing
- RSG XR
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.